OOVA
OOVA is a women's health technology company that has developed an FDA-cleared at-home hormone monitoring platform using AI-powered smartphone scanning of multi-hormone urine test strips, serving women tracking fertility, perimenopause, and hormone optimization via a dual DTC and healthcare provider channel.
- Company typePrivate
- Founded2019
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What OOVA does
OOVA is a women's health technology company that has developed an at-home hormone monitoring platform combining a proprietary lateral flow immunoassay with AI-powered smartphone scanning. Founded in 2019 and headquartered in New York, the company serves women trying to conceive, women navigating perimenopause, and women seeking general hormone optimization. The core technology quantitatively measures three reproductive hormones — luteinizing hormone (LH), E3G (an estrogen metabolite), and PdG (a progesterone metabolite) — from urine samples, with third-party-validated 99% correlation to blood testing. The platform consists of three test kit SKUs (Fertility, Perimenopause, Hormone Optimization) paired with a companion mobile app that uses computer vision to interpret test strip scans and machine learning to build personalized hormone baselines that improve with continued use. The company has secured 510(k) FDA clearance and developed its assay in collaboration with Mount Sinai physicians.
OOVA operates a dual go-to-market combining direct-to-consumer e-commerce (shop.oova.life, iOS/Android apps) with a B2B healthcare provider channel anchored by the HIPAA-compliant Oova360 dashboard, which delivers real-time patient hormone data to clinicians. Revenue is generated through one-time test kit purchases and the Oova Membership monthly subscription, which bundles a 30% kit discount with 1:1 expert consultations and peer community access. The company has raised $11.5M in total funding, including a $10.3M Series A led by Spero Ventures in June 2023 with participation from Connecticut Innovations, Jefferson Health System, Samsung NEXT's Q Fund, US Fertility, and Virgin Group. Distribution spans 400+ clinics and 600+ providers, with research collaborations at Stanford, UCSF, Mass General, University of Utah Health, and Mount Sinai. The company has earned clinical recognition from ACOG, ASRM, and The Menopause Society, and was awarded the 2026 Nestlé Health Science Innovate Forward Women's Health Challenge.
OOVA firmographics
Firmographics- Name
- OOVA
- Legal name
- OOVA, Inc.
- Website
- https://oova.life
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OOVA is a women's health technology company that has developed an FDA-cleared at-home hormone monitoring platform using AI-powered smartphone scanning of multi-hormone urine test strips, serving women tracking fertility, perimenopause, and hormone optimization via a dual DTC and healthcare provider channel.
- Ownership category
- akta.pro rank
OOVA industry classification
Industry- Product category
- Women's Health Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection) (HLAHAOAF)
- akta.pro secondary industries
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), At-Home Lab Testing & Diagnostics-Integrated Virtual Care (HLALAAAE)
Keywords
Where OOVA is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
OOVA business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D
Revenue model
- At-Home Hormone Test Kits: One-time purchase of hormone test kits (Fertility, Perimenopause, Hormone Optimization). Test kits are FSA/HSA eligible. The company sells directly through its e-commerce platform.
- Oova Membership Subscription: Monthly subscription providing 30% off test kits, peer community access, 1:1 consultations with hormone experts, and member-exclusive events. This is the primary recurring revenue stream.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | One-time kit purchase |
| Subscription | Monthly | Oova Membership |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
OOVA product offering
Product offeringCore offering
OOVA manufactures at-home hormone diagnostic test kits that quantitatively measure luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) from urine samples using patented biochemical assay technology. The physical test strips are scanned via a free AI-powered smartphone app that delivers personalized hormone insights and clinical-grade data to users, with a HIPAA-compliant provider dashboard enabling real-time sharing with healthcare providers.
Product overview
Oova is a women's health technology company offering an at-home hormone monitoring platform consisting of test kits and a companion AI-powered smartphone app. The core product portfolio includes the Oova Fertility Hormone Kit and Oova Perimenopause Hormone Kit, which measure luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) through urine test strips. These kits pair with the free Oova App, which uses computer vision to scan and interpret test results and delivers personalized hormone insights. An optional Oova Membership provides subscription-based access to test kits at a discount plus expert consultations. The Oova360 Provider Dashboard enables healthcare providers to receive real-time patient data, creating a connected ecosystem for fertility tracking and perimenopause management.
Differentiator
Problem solved
Functional benefit
Products and services
- Oova Fertility Hormone Kit An at-home hormone testing kit that quantitatively measures luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) through urine samples to help women identify their fertile window, predict ovulation, and track cycles for conception. The kit pairs with a smartphone app that uses AI image processing to interpret results and provides personalized insights.
- Oova Perimenopause Hormone Kit An at-home hormone monitoring kit designed for women navigating perimenopause. Measures the same three hormones (LH, E3G, PdG) through urine to help track hormonal fluctuations, map menopause transition stages, and connect symptoms to hormone changes. Provides clinical-grade insights for the menopause transition.
- Oova Hormone Optimization A tracking experience for women who want to better understand symptoms and hormone patterns at any life stage, not just during perimenopause. Focuses on symptom tracking, hormone insights, and overall wellbeing, allowing users to understand how hormones influence migraines, mood, sleep, energy, and metabolism.
- Oova App A free AI-powered mobile application that serves as the core platform for all Oova products. The app scans test strips using the smartphone camera, interprets hormone levels through computer vision, provides personalized insights via AI-driven baseline learning, and generates provider-ready reports. Available on iOS and Android.
- Oova Membership A monthly subscription offering 30% off monthly test kits, access to peer community, 1:1 consultations with hormone experts, and member-exclusive events. Provides a more robust fertility and hormone optimization solution compared to one-time purchases.
- Oova Provider Dashboard (Oova360) A HIPAA-compliant clinician dashboard enabling real-time patient data sharing. Healthcare providers can remotely monitor their patients' ovulation patterns, track treatment progress, and receive hormone data directly from patients' Oova kits.
Quantifiable outcome
- +46% increase in successful pregnancies for fertility patients
- +5 more outcomes
Companies that use OOVA
Customer profileNamed customers11 records
Segments4 records
Ideal customer profiles3 records
OOVA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
OOVA partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core, flagship and minor.
- Nestlé Health SciencecoreWon Nestlé Health Science's Innovate Forward: Women's Health Challenge. Receives six-month mentorship engagement and membership in the Institute's Food & Nutrition Innovation Council at Tufts University Friedman School.
- Mount Sinai Health SystemflagshipOOVA technology developed by physicians and biomedical engineers at Mount Sinai. Mt. Sinai physicians developed the patented biochemical assay and OOVA is backed by peer-reviewed science from one of the nation's top medical institutions.
- Wu Tsai Human Performance AlliancecoreResearch collaboration on women's health and hormone monitoring studies.
- New Hope Fertility CentercoreCollaborated on validating urine-serum LH and PdG correlation during IVF stimulation. White paper published on at-home hormone testing against serum standards.
- Jefferson HealthcoreMajor health system partner using OOVA for patient hormone monitoring. Featured on OOVA's provider page.
- Massachusetts General HospitalcoreMajor health system partner collaborating on OOVA technology and research.
- University of Utah HealthcoreResearch partner studying menstrual cycle and ovulation trends using OOVA's hormone monitoring.
- Stanford MedicinecoreResearch collaboration on hormone monitoring technology and clinical studies.
- UCSFcoreResearch partner studying reproductive and hormonal health through OOVA technology.
- University at BuffalominorAcademic research partner contributing to clinical studies on hormone monitoring.
- Penn StateminorAcademic research partner contributing to clinical studies on hormone monitoring.
- TiacoreWomen's health clinic partner offering OOVA hormone testing services to their patients as part of care delivery.
- EvernowminorMenopause care platform partner offering OOVA technology to their patient population.
- ASRMcoreAmerican Society for Reproductive Medicine - OOVA research presented at ASRM conferences, providing clinical credibility and scientific validation.
- ACOGcoreAmerican College of Obstetricians and Gynecologists - OOVA recognized by ACOG for clinical validation of hormone monitoring technology.
- The Menopause SocietycoreOOVA's perimenopause tracking technology validated by The Menopause Society (formerly NAMS). OOVA research published in ACOG Green Journal.
Scale indicators13 records
Recent moves6 records
Expansion highlights7 records
OOVA competitors and assessment
Company assessmentEmerging players
- Eli Health: Eli Health is developing at-home continuous hormone monitoring via saliva. Emerging player in the same at-home hormone insight category, with overlapping perimenopause and fertility positioning though different sample type.
- Hertility Health: Hertility Health provides at-home hormone testing combined with teleconsults for women navigating fertility, perimenopause, and PCOS. Comparable target audience and DTC-plus-clinic model, but operates primarily in the UK and is at earlier stage.
Direct peers
- Inito: Inito provides a connected at-home fertility monitor measuring multiple hormones (LH, E3G, PdG) via urine test strips scanned in a smartphone-connected reader. Closely comparable on multi-hormone at-home fertility testing.
- Proov: Proov sells at-home PdG/progesterone test strips and a companion app to confirm ovulation. Direct competitor in the at-home hormone testing category serving women trying to conceive, with overlapping hormone readouts.
- Mira: Mira offers at-home quantitative hormone testing (LH, E3G, PdG) for fertility using a connected wand + app. Closest direct competitor to OOVA in the at-home multi-hormone fertility testing category with similar target customer and price point.
- Premom (Easy@Home): Premom combines ovulation test strips with an AI-driven cycle tracking app. Competes directly on at-home ovulation tracking for women trying to conceive, with lower-cost test strips and a free app versus OOVA's premium positioning.
Broad incumbents
- Modern Fertility (Ro): Modern Fertility, acquired by Ro, offers hormone testing primarily through mail-in blood panels, plus a broader women's health telehealth platform. Comparable target market (women tracking fertility hormones) but different sample type (blood vs. urine) and a much larger parent with broader portfolio.
- Clearblue: Clearblue is the established incumbent in at-home ovulation and pregnancy testing. Massive retail distribution and brand recognition in the same consumer category, but uses traditional single-hormone binary tests rather than OOVA's quantitative multi-hormone approach.
- Labcorp: Labcorp is one of the largest clinical diagnostic laboratories in the US, offering serum hormone testing ordered by physicians. Broad incumbent in the underlying women's reproductive hormone testing market that OOVA is disrupting with at-home urine testing.
- Ro: Ro is a multi-vertical telehealth platform (including Roman, Rory, Modern Fertility) covering men's and women's health, including fertility and perimenopause. Broad incumbent with overlapping women's hormone offerings and far greater capital and distribution.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
OOVA social profiles
Digital presenceOOVA financial estimates
Financial estimateRevenue estimate
Valuation estimate
OOVA leadership team
Management profileNumber of profiles
Profiles4 records
OOVA funding detail
Funding detailFunding overview
Funding rounds6 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OOVA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OOVA
What does OOVA do?
OOVA manufactures at-home hormone diagnostic test kits that quantitatively measure luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) from urine samples using patented biochemical assay technology. The physical test strips are scanned via a free AI-powered smartphone app that delivers personalized hormone insights and clinical-grade data to users, with a HIPAA-compliant provider dashboard enabling real-time sharing with healthcare providers.
Is OOVA a public or private company?
OOVA is a private company. It is classified as venture growth investor backed and is currently operating.
When was OOVA founded?
OOVA was founded in 2019. It employs 1 to 10 people.
Where is OOVA based?
OOVA is headquartered in New York, United States, in the North America region.
How does OOVA make money?
Two revenue lines are on record. At-Home Hormone Test Kits are the primary driver. The others are oova Membership Subscription.
Who are OOVA's main competitors?
Emerging players on record are Eli Health and Hertility Health. Direct peers are Inito, Proov, Mira and Premom (Easy@Home). Broad incumbents are Modern Fertility (Ro), Clearblue, Labcorp and Ro.
Does OOVA have an API?
No public API is recorded for OOVA.
What industry is OOVA in?
OOVA's product category is Women's Health Diagnostics. Its primary akta.pro industry code is HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection), with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 325413 and its SIC code is 2835.